Pulmonary nodules in a histoplasmosis-endemic area: Diagnostic challenges and lessons from a case series [0.03%]
组织胞浆菌病流行区的肺结节：诊断挑战及病例系列带来的启示
Sylvain Neveu,Quentin Lafarge,Marwan Haboub et al.
Sylvain Neveu et al.
Introduction: In histoplasmosis-endemic regions, pulmonary nodules often raise concern for malignancy. Distinguishing benign infectious granulomas from neoplastic lesions while limiting invasiveness is a major diagnostic ...
Real-world evidence on hospitalization, infection, and vascular outcomes among interstitial lung disease subtypes [0.03%]
特发性肺纤维化及其他间质性肺病亚型患者的住院、感染及血管事件的现实世界研究
Wen-Cheng Chao,Shu-Yi Liao
Wen-Cheng Chao
Background and objective: Interstitial lung diseases (ILDs) consist of idiopathic pulmonary fibrosis (IPF) and non-IPF ILDs. While pulmonary complications in IPF are relatively well-studied, there is a need for research o...
Second-line treatment after first-line osimertinib without a targetable resistance mechanism: what remains standard? [0.03%]
一线奥希替尼治疗后缺乏可靶向耐药机制的二线治疗：何为标准？
Julien Ancel,Simon Baldacci
Julien Ancel
Characteristics of lung nodules detected by low-dose CT scan: Results from the French lung cancer screening study DEP KP-80 [0.03%]
法国肺部癌症筛查研究DEP KP-80中低剂量CT检查发现的肺结节的特点
Nicolas Storme,Marianne Auquier,Sébastien Couraud et al.
Nicolas Storme et al.
Background: DEP KP-80 is a real-world prospective study evaluating the effectiveness of organized lung cancer screening using low-dose chest CT (LDCT) across a French administrative department. Final results were publishe...
Trends in annual prevalence and incidence of pharmacologically treated idiopathic pulmonary fibrosis in Greece (2019-2023): A nationwide e-prescription study [0.03%]
希腊2019-2023年药物治疗特发性肺纤维化的年度患病率和发病率趋势：一项全国范围内的电子处方研究
Georgia Kourlaba,Garyfallia Stefanou,Stylianos Ravanidis et al.
Georgia Kourlaba et al.
Background: Limited data is available on the epidemiological burden of idiopathic pulmonary fibrosis (IPF) for countries such as Greece. As such, the objective of the current retrospective observational cohort study was t...
Design of PROGRESSION-IPF: A pragmatic, open-label, randomized trial of patients with progressive disease in idiopathic pulmonary fibrosis [0.03%]
PROGRESSION-IPF研究设计：特发性肺纤维化患者疾病进展期开放标签随机试验的设计
Vincent Cottin,Bruno Crestani,Carole Planès et al.
Vincent Cottin et al.
Background: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic interstitial lung disease with poor prognosis. Although antifibrotic therapies such as pirfenidone and nintedanib slow lung function decline, optim...
Macrolide maintenance therapy in chronic inflammatory airway diseases: A survey of French pulmonologist's practices [0.03%]
法国呼吸科医师在慢性气道炎症性疾病维持治疗中超 macrolides 使用的调查
Benoit Douvry,Claire Andrejak,Marlène Murris-Espin et al.
Benoit Douvry et al.
Hemoptysis risk in lung cancer associated thrombosis patients who initiated anticoagulant therapy [0.03%]
开始抗凝治疗的肺癌伴发血栓患者咯血风险
Christophe Marie-Sainte,Anne-Laure Desage,Valentine Mismetti et al.
Christophe Marie-Sainte et al.
Background: Lung cancer (LC) is linked to an increased risk of cancer-associated thrombosis (L-CAT), requiring anticoagulant therapy (AT). Patients treated with AT have an increased risk of bleeding. Hemoptysis is common ...
Assessment of the interobserver reliability in discharge decision-making for patients undergoing thoracic surgery based on chest ultrasound compared to chest X-ray findings [0.03%]
基于胸部超声与胸部X线检查结果的胸外科手术患者出院决策的组间信度评估
Zaineb Guesmi,Martin Faure,Julia Ballouhey et al.
Zaineb Guesmi et al.
Background: Safe authorization of patient discharge after thoracic surgery must be ensured following chest tube removal. This decision is commonly based on chest X-ray findings. Chest ultrasound (US) has emerged as a pote...
Prognostic value of metabolic activity in noncancerous lung areas for stage I lung cancer [0.03%]
一期肺癌患者非肿瘤区域代谢活性的预后价值
Takashi Yamamichi,Yoshihisa Shimada,Hideyuki Furumoto et al.
Takashi Yamamichi et al.
Background: Tumor maximum standardized uptake value (tumor-SUVmax) on ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) is an established prognostic marker in lung cancer. However, met...